Fusion Antibodies – ‘significantly behind expectations’… countdown to insolvency accelerates
Previously writing on antibody contract research organisation Fusion Antibodies (FAB), last month I noted the shares rising from 45p on an “R&D update”, but wrote attempted ramptastic?, how “sufficient” is the cash now?. Today a “trading statement” and the shares currently more than 30% lower towards 30p.
- By Steve Moore
- 2023-03-06 11:25:29